Fig. 6.

Systematic analysis of ranked inferred kinases and their INKA metrics in relation to drug EC₅₀ values. Percentage potential kinase inhibition for quizartinib, ponatinib, ibrutinib, tofaitinib and GDC0994 was separately calculated for “Kinome”-, “Activation loop”-, “PhosphoSitePlus” (PSP)- and “NetworKIN′ (NWK)-based metrics of kinase activity as well as for the aggregate INKA score. This involves, for a given metric/score, taking the ratio of the summed values of kinases in the target space of a kinase inhibitor and the summed values of all kinases within a cell line. Log EC₅₀ values for quizartinib, ponatinib, ibrutinib, tofaitinib and GDC0994 were compared with the percentage potential kinase inhibition of these drugs for the AML cell lines using Pearson correlation.